跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,280 条关于
“C3G/IC-MPGN”
全部
1,280
临床试验
769
药物
366
机构
9
资讯
136
去年
Pegcetacoplan Shows Promise in C3G and IC-MPGN Treatment: VALIANT Trial
去年
Apellis Pharmaceuticals' C3G/IC-MPGN Drug Shows Promise Amidst Syfovre Setbacks
去年
EMA Validates Aspaveli® Extension Application for Rare Kidney Diseases C3G and IC-MPGN
去年
Pegcetacoplan Shows Promise in Treating Rare Kidney Diseases C3G and IC-MPGN
去年
Pegcetacoplan Shows Significant Treatment Effect in C3G and IC-MPGN Patients
去年
Pegcetacoplan Shows Strong Results in VALIANT Trial for C3G and IC-MPGN
去年
Pegcetacoplan Shows Strong Efficacy in C3G and IC-MPGN Patients: VALIANT Trial Results
去年
Aspaveli Demonstrates Sustained 68% Proteinuria Reduction in Phase 3 VALIANT Trial for Rare Kidney Diseases
去年
Apellis Secures $300 Million in Non-Dilutive Financing Through Sobi Royalty Agreement for Rare Kidney Disease Therapy
去年
Emerging Therapies Show Promise for Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
第 1 页,共 14 页
上一页
下一页